Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Silverback TherapeuticsBioAtlaGracell BiotechnologiesiTeos TherapeuticsVor Biopharma
SymbolNASDAQ:SBTXNASDAQ:BCABNASDAQ:GRCLNASDAQ:ITOSNYSE:VOR
Price Information
Current Price$38.29$46.04$12.94$23.99$33.72
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.71.71.51.91.9
Analysis Score3.53.53.53.54.3
Community Score4.45.04.03.83.6
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.01.71.7
Earnings & Valuation Score0.60.00.00.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$50.25$58.00$34.50$49.40$48.20
% Upside from Price Target31.24% upside25.98% upside166.62% upside105.92% upside42.94% upside
Trade Information
Market Cap$1.34 billion$1.55 billion$848.39 million$842.03 million$1.25 billion
BetaN/AN/AN/AN/AN/A
Average Volume238,225281,749150,995281,727293,453
Sales & Book Value
Annual RevenueN/AN/AN/AN/AN/A
Price / SalesN/AN/AN/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/AN/AN/AN/AN/A
Price / BookN/AN/AN/AN/AN/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AN/AN/AN/AN/A
Trailing P/E Ratio0.000.000.000.000.00
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/AN/A
Quick RatioN/AN/AN/AN/AN/A
Ownership Information
Institutional Ownership PercentageN/AN/AN/A71.07%N/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees54N/AN/A5570
Shares Outstanding34.90 million33.66 million65.56 million35.10 million37.13 million
Next Earnings Date7/5/2021 (Estimated)N/AN/A6/23/2021 (Estimated)6/24/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Vor Biopharma (NYSE:VOR) Trading 9.9% Higher Vor Biopharma (NYSE:VOR) Trading 9.9% Higher
americanbankingnews.com - April 14 at 2:34 PM
Vor Biopharma (NYSE:VOR) Shares Gap Down to $32.13Vor Biopharma (NYSE:VOR) Shares Gap Down to $32.13
americanbankingnews.com - April 13 at 1:42 PM
Vor Biopharma (NYSE:VOR)  Shares Down 4.5% Vor Biopharma (NYSE:VOR) Shares Down 4.5%
americanbankingnews.com - April 7 at 12:32 PM
Vor Biopharma (NYSE:VOR) Shares Gap Down to $43.10Vor Biopharma (NYSE:VOR) Shares Gap Down to $43.10
americanbankingnews.com - April 5 at 11:40 AM
Vor Biopharma (NYSE:VOR) Trading Down 8%Vor Biopharma (NYSE:VOR) Trading Down 8%
americanbankingnews.com - April 1 at 12:36 PM
Vor Biopharma (NYSE:VOR) Trading 7% Higher Vor Biopharma (NYSE:VOR) Trading 7% Higher
americanbankingnews.com - March 31 at 12:00 PM
Vor Biopharma IncVor Biopharma Inc
reuters.com - March 30 at 10:32 PM
Vor Biopharma (NYSE:VOR) Sees Strong Trading VolumeVor Biopharma (NYSE:VOR) Sees Strong Trading Volume
americanbankingnews.com - March 30 at 11:45 AM
B. Riley Begins Coverage on Vor Biopharma (NYSE:VOR)B. Riley Begins Coverage on Vor Biopharma (NYSE:VOR)
americanbankingnews.com - March 30 at 9:44 AM
Vor Biopharma (NYSE:VOR) Research Coverage Started at B. RileyVor Biopharma (NYSE:VOR) Research Coverage Started at B. Riley
marketbeat.com - March 30 at 8:26 AM
Vor Biopharma (NYSE:VOR) Shares Gap Down to $39.12Vor Biopharma (NYSE:VOR) Shares Gap Down to $39.12
americanbankingnews.com - March 26 at 12:02 PM
Vor Biopharma Reports FY20 Net Loss Of $43.3M Compared To $10.8M YoYVor Biopharma Reports FY20 Net Loss Of $43.3M Compared To $10.8M YoY
benzinga.com - March 25 at 8:48 PM
Vor Reports Fiscal Year 2020 Financial ResultsVor Reports Fiscal Year 2020 Financial Results
finance.yahoo.com - March 25 at 8:48 PM
Vor Biopharma (NYSE:VOR) Now Covered by B. RileyVor Biopharma (NYSE:VOR) Now Covered by B. Riley
americanbankingnews.com - March 24 at 9:03 PM
Vor Biopharma Inc Registered Shs OverweightVor Biopharma Inc Registered Shs Overweight
markets.businessinsider.com - March 5 at 8:32 AM
Vor Biopharma Inc Registered Shs SellVor Biopharma Inc Registered Shs Sell
markets.businessinsider.com - March 4 at 10:03 AM
Vor Biopharma Inc Registered Shs BuyVor Biopharma Inc Registered Shs Buy
markets.businessinsider.com - March 4 at 10:03 AM
Vor Biopharma Announces Participation at Cowen 41st Annual Health Care ConferenceVor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference
finance.yahoo.com - March 1 at 8:09 PM
Biopharma Companies Flood Nasdaq’s IPO Pipeline in FebruaryBiopharma Companies Flood Nasdaq’s IPO Pipeline in February
nasdaq.com - February 26 at 6:04 PM
PureTech Health PLC - Vor Closes Over $200M Initial Public OfferingPureTech Health PLC - Vor Closes Over $200M Initial Public Offering
proactiveinvestors.co.uk - February 10 at 1:38 PM
PureTech sells down Karuna stake as Vor closes IPOPureTech sells down Karuna stake as Vor closes IPO
sharecast.com - February 10 at 8:37 AM
Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to ...Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to ...
apnews.com - February 10 at 8:37 AM
PureTech Founded Entity Vor Biopharma Closes Over $200M Initial Public OfferingPureTech Founded Entity Vor Biopharma Closes Over $200M Initial Public Offering
businesswire.com - February 10 at 8:37 AM
Vor Biopharma Inc Registered Shs Stock , VORVor Biopharma Inc Registered Shs Stock , VOR
markets.businessinsider.com - February 9 at 7:41 PM
Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional SharesVor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares
finance.yahoo.com - February 9 at 7:41 PM
VOR Stock Price Increased 108.33%: Why It HappenedVOR Stock Price Increased 108.33%: Why It Happened
pulse2.com - February 8 at 8:26 AM
DateCompanyBrokerageAction
4/13/2021Silverback TherapeuticsSVB LeerinkBoost Price Target
3/30/2021Silverback TherapeuticsStifel NicolausBoost Price Target
3/30/2021Silverback TherapeuticsThe Goldman Sachs GroupBoost Price Target
12/29/2020Silverback TherapeuticsHC WainwrightInitiated Coverage
4/1/2021BioAtlaBTIG ResearchBoost Price Target
1/11/2021BioAtlaCredit Suisse GroupInitiated Coverage
1/11/2021BioAtlaJefferies Financial GroupInitiated Coverage
1/11/2021BioAtlaJPMorgan Chase & Co.Initiated Coverage
2/3/2021Gracell BiotechnologiesCitigroupInitiated Coverage
2/2/2021Gracell BiotechnologiesPiper SandlerInitiated Coverage
2/2/2021Gracell BiotechnologiesWells Fargo & CompanyInitiated Coverage
3/25/2021iTeos TherapeuticsWedbushBoost Price Target
10/7/2020iTeos TherapeuticsRobert W. BairdInitiated Coverage
3/30/2021Vor BiopharmaB. RileyInitiated Coverage
3/9/2021Vor BiopharmaBarclaysInitiated Coverage
3/8/2021Vor BiopharmaEvercore ISIInitiated Coverage
(Data available from 4/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.